IGF-1 LR3 (1 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously, typically in the morning or post-workout with food intake to mitigate insulin-like effects on blood glucose. For 10 unit (0.10 mL) or smaller administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

1. Draw 1 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall to avoid foaming; do not shake.
3. Gently swirl or roll until the lyophilized powder dissolves completely into a clear solution.
4. Label the vial with reconstitution date and refrigerate at 2 to 8 °C, protected from light.
5. Use within 30 days of reconstitution; for longer storage, prepare aliquots and freeze at -20 °C for up to 3 to 6 months. At 1 mg/mL, 1 unit = 0.01 mL » 10 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C or colder in dry, dark conditions for up to 12 months; short-term storage at 2

to 8 °C for several months is acceptable.

• Reconstituted: refrigerate at 2 to 8 °C immediately after mixing; use within 30 days for optimal potency.
• Extended storage: prepare sterile aliquots and freeze at -20 °C; aliquots remain stable for 3 to 6 months.

Never refreeze a thawed vial.

• Allow frozen vials to reach room temperature before opening to minimize condensation; inspect solution

for clarity (discard if cloudy or contains particles).

• Keep all vials protected from light and maintain cold chain during storage.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (IGF-1 LR3, 1 mg each):

• 8 weeks: ~3 vials (~2.24 mg total needed).
• 12 weeks: ~4 vials (~3.64 mg total needed).
• 16 weeks: ~6 vials (~5.04 mg total needed).

Insulin Syringes (U-100, 0.5 mL or 1 mL):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (3 vials): 1 bottle. 12 weeks (4 vials): 2 bottles. 16 weeks (6 vials): 2 bottles.

Alcohol Swabs:

• Per week: 14 swabs. 16 weeks: 224 swabs (3 x 100-count boxes).

Additional:

• Sharps container for safe disposal of used needles and syringes.
• Fast-acting carbohydrate source (glucose tablets or juice) on hand during cycle to address potential

hypoglycemia symptoms, especially during dose titration.

Important Notes

Practical considerations for consistency and safety.

• Sterile technique: Use new sterile insulin syringes for each injection; dispose immediately in a sharps

container.

• Site rotation: Systematically rotate between abdomen, outer thighs, and upper arms.
• Hypoglycemia awareness: Be vigilant for signs of low blood sugar (shakiness, dizziness, sweating)

especially during dose escalation; have fast-acting carbohydrates readily available.

• Timing with meals: Administer with or shortly after food intake to mitigate insulin-like effects on blood

glucose.

• Documentation: Keep a daily log of dose, injection site, and any observed effects.
• Never exceed conservative dosing: Doses above 50 to 60 mcg/day lack robust clinical research

support and may substantially increase adverse effect risk.

How This Works

IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 engineered with an N-terminal extension (13 amino acids) and a glutamic acid substitution at position 3, resulting in significantly reduced binding affinity to IGF binding proteins. This modification extends the peptide's half-life from minutes (native IGF-1) to several hours and enhances systemic bioavailability. The extended circulation time allows for once-daily administration protocols in research settings. Unlike native IGF-1, which requires frequent dosing, IGF-1 LR3 maintains more stable plasma levels throughout the day. The peptide exhibits anabolic and metabolic activities through IGF-1 receptor binding, though it has never been approved for therapeutic human use and remains confined to research applications. The insulin-like properties necessitate careful attention to blood glucose management, particularly during initial dosing and titration phases.

Benefits & Side Effects

Observations from preclinical and clinical literature on IGF-1 and its analogs.

• Enhanced anabolic signaling and protein synthesis in target tissues.
• Extended bioavailability compared to native IGF-1 due to reduced binding protein interaction.
• Metabolic effects through IGF-1 receptor pathways.
• Hypoglycemia risk: The most significant concern with IGF-1 LR3 is its insulin-like effect on blood

glucose; symptoms may include shakiness, confusion, sweating, or dizziness. Always administer with

food and monitor for glucose-related symptoms.

• No FDA approval: IGF-1 LR3 has never received regulatory approval for human therapeutic use and is

restricted to research applications.

• Injection site reactions: Mild local irritation, redness, or discomfort may occur.
• Dose-dependent effects: Safety concerns increase substantially at doses exceeding 50 to 60 mcg/day;

conservative dosing strongly recommended.

• Receptor desensitization: Continuous use beyond 6 to 8 weeks may lead to diminished response;

cycling protocols (8 on / 4 to 8 off) are commonly employed.

Lifestyle Factors

Complementary strategies for best outcomes.

• Nutrition: Maintain adequate protein intake (1.6 to 2.2 g/kg body weight); ensure regular meal timing to

manage blood glucose stability.

• Training: Combine resistance training with appropriate recovery periods; IGF-1 signaling pathways are

activated by mechanical loading.

• Sleep & Recovery: Prioritize 7 to 9 hours of quality sleep nightly to optimize endogenous growth factor

production.

• Hydration: Maintain consistent hydration to support metabolic function and peptide distribution.
• Glucose monitoring: Consider periodic blood glucose checks during dose titration.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports (Biomolecules / MDPI).
2. Insulin-like growth factor 1 (IGF-1) and long chain IGF (LR3IGF-1): Medical information (Dopinglinkki / FINCIS).
3. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I for anti-doping purposes (Drug Testing and Analysis).
4. Mecasermin (Subcutaneous): proper use, dosing, and hypoglycemia management (Mayo Clinic / Drugs.com). IGF-1 LR3 (1 mg vial) Once-daily subcutaneous protocol for long-acting IGF-1 analog anabolic and metabolic research. IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified analog of human IGF-1 with significantly extended half-life, studied for its anabolic and metabolic effects. This synthetic variant exhibits reduced binding to IGF binding proteins, allowing enhanced bioavailability and systemic activity. This educational protocol presents a once-daily subcutaneous approach with conservative titration for research applications. Protocol Overview Concise summary of the regimen. Goal: Support anabolic processes and metabolic function through enhanced IGF-1 activity with extended bioavailability. Schedule: Daily subcutaneous injections for 8 weeks (standard cycle); may extend to 12 weeks with appropriate off-periods. Dose Range: 20 to 50 mcg daily with gradual titration; conservative protocols remain at or under 50 mcg/day. Reconstitution: 1 mL per 1 mg vial (1 mg/mL or 1000 mcg/mL). Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze-thaw cycles. Cycling: Common approach is 8 weeks on, 4 to 8 weeks off to prevent receptor desensitization. Dosing & Reconstitution Guide Standard / gradual approach (1 mL = 1 mg/mL). WEEK DAILY DOSE UNITS PER INJECTION Weeks 1 to 2 20 mcg 2 units (0.02 mL) Weeks 3 to 4 40 mcg 4 units (0.04 mL) Weeks 5 to 8 50 mcg 5 units (0.05 mL) Frequency: Inject once daily subcutaneously, typically in the morning or post-workout with food intake to mitigate insulin-like effects on blood glucose. For 10 unit (0.10 mL) or smaller administrations, consider 30- or 50-unit insulin syringes for improved readability. Reconstitution Steps